| Target Price | $1.40 |
| Price | $1.66 |
| Deviation |
15.82%
register free of charge
|
| Number of Estimates | 4 |
|
4 Analysts have issued a price target LAVA Therapeutics NV 2026 .
The average LAVA Therapeutics NV target price is $1.40.
This is
15.82%
register free of charge
$1.58
5.12%
register free of charge
$1.25
24.55%
register free of charge
|
|
| A rating was issued by 7 analysts: 0 Analysts recommend LAVA Therapeutics NV to buy, 4 to hold and 3 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the LAVA Therapeutics NV stock has an average upside potential 2026 of
15.82%
register free of charge
|
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Aug 05 2025 |
| Jefferies |
Locked
➜
Locked
|
Locked | Aug 05 2025 |
| JMP Securities |
Locked
➜
Locked
|
Locked | May 15 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 31 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Feb 27 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Dec 20 2024 |
| Leerink Partners |
Locked
➜
Locked
|
Locked | Dec 12 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Aug 05 2025 |
|
Locked
Jefferies:
Locked
➜
Locked
|
Aug 05 2025 |
|
Locked
JMP Securities:
Locked
➜
Locked
|
May 15 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 31 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Feb 27 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Dec 20 2024 |
|
Locked
Leerink Partners:
Locked
➜
Locked
|
Dec 12 2024 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


